VA Cooperative Studies Program (CSP)

Published Studies

These are the last three years of primary analysis publication(s) for CSP research studies. A link to the full text version is provided for those that don’t require a subscription to the journal. A link to a summary is provided for the few where a subscription is required.

CSP #572: VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)

• Zisook, S., Moutier, C.Y., Rush, A.J., Johnson, G.R., Tal, I., Chen, P.J., Davis, L.L., Hicks, P.B., Wilcox, J., Planeta, B. and Lauro, K.W., 2024. Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial. Psychological medicine, 54(6), pp.1172-1183. doi:10.1017/S0033291723003008

CSP #592: Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

• Singh, S.N., Wininger, M., Raitt, M., Adabag, S., Moore, H., Rottman, J.N., Scrymgeour, A., Zhang, J., Zheng, K., Guarino, P. and Kyriakides, T.C., 2024. Efficacy and safety of implantable cardioverter-defibrillator implantation in the elderly—The I-70 Study: A randomized clinical trial. Heart Rhythm O2, 5(6), pp.365-373. doi: 10.1016/j.hroo.2024.04.010

CSP #2003: Exoskeletal-Assisted Walking in Persons with Spinal Cord Injuries (SCI): Impact on Quality of Life

• Spungen, A.M., Dematt, E.J., Biswas, K., Jones, K.M., Mi, Z., Snodgrass, A.J., Morin, K., Asselin, P.K., Cirnigliaro, C.M., Kirshblum, S. and Gorman, P.H., 2024. Exoskeletal-assisted walking in veterans with paralysis: a randomized clinical trial. JAMA network open, 7(9), pp.e2431501-e2431501. doi: 10.1001/jamanetworkopen.2024.31501

CSP #2004: Microbiota or Placebo after Antimicrobial Therapy for Recurrent C. difficile at Home (MATCH)

• Drekonja, D.M., Shaukat, A., Huang, Y., Zhang, J.H., Reinink, A.R., Nugent, S., Dominitz, J.A., Davis-Karim, A., Gerding, D.N. and Kyriakides, T.C., 2025.A randomized controlled trial of efficacy and safety of Fecal Microbiota Transplant for preventing recurrent Clostridioides difficile infection. Clinical Infectious Diseases, 80(1), pp.52-60. doi: 10.1093/cid/ciaf032.

CSP #2006: Genomics of Gulf War Illness in Veterans

• Harrington, K.M., Quaden, R., Steele, L., Helmer, D.A., Hauser, E.R., Ahmed, S.T., Aslan, M., Radhakrishnan, K., Honerlaw, J., Nguyen, X.M.T. and Muralidhar, S., 2024. The Million Veteran Program 1990–1991 Gulf War Era Survey: An Evaluation of Veteran Response, Characteristics, and Representativeness of the Gulf War Era Veteran Population. International Journal of Environmental Research and Public Health, 21(1), p.72. doi: 10.3390/ijerph21010072

• Steele, L., Quaden, R., Ahmed, S.T., Harrington, K.M., Duong, L.M., Ko, J., Gifford, E.J., Polimanti, R., Gaziano, J.M., Aslan, M. and Helmer, D.A., 2024. Association of deployment characteristics and exposures with persistent ill health among 1990-1991 Gulf War veterans in the VA Million Veteran Program. Environmental Health, 23(1), p.92. doi: 10.1186/s12940-024-01118-7

• Wendt, F.R., Pathak, G.A., Vahey, J., Qin, X., Koller, D., Cabrera-Mendoza, B., Haeny, A., Harrington, K.M., Rajeevan, N., Duong, L.M. and Levey, D.F., 2023. Modeling the longitudinal changes of ancestry diversity in the Million Veteran Program. Human Genomics, 17(1), p.46. doi: 10.1186/s40246-023-00487

CSP #2038: COVID-19 Pharmacotherapy Effectiveness in the VA Healthcare System (COPE-VA)

• Ioannou, G.N., Berry, K., Rajeevan, N., Li, Y., Yan, L., Huang, Y., Bui, D., Hynes, D.M., Rowneki, M., Hickok, A. and Niederhausen, M., 2025. Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras. Clinical Infectious Diseases, p.ciaf087. doi: 10.1093/cid/ciaf087
  
  
• Bajema, K.L., Yan, L., Li, Y., Argraves, S., Rajeevan, N., Fox, A., Vergun, R., Berry, K., Bui, D., Huang, Y. and Lin, H.M., 2025. Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study. The Lancet Infectious Diseases, Jan 20:S1473-3099(24)00796-5. doi: 10.1016/s1473-3099(24)00796-5 
  
  
• Bajema, K.L., Bui, D.P., Yan, L., Li, Y., Rajeevan, N., Vergun, R., Berry, K., Huang, Y., Lin, H.M., Aslan, M. and Ioannou, G.N., 2025. Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus. JAMA Internal Medicine,185(3):324–334. doi:10.1001/jamainternmed.2024.7452
  
  
• Bui, D.P., Bajema, K.L., Huang, Y., Yan, L., Li, Y., Rajeevan, N., Berry, K., Rowneki, M., Argraves, S., Hynes, D.M. and Huang, G., 2024. Development of a prediction model for 30-day COVID-19 hospitalization and death in a national cohort of Veterans Health Administration patients–March 2022—April 2023 PloS one, 19(10), p.e0307235. doi: 10.1371/journal.pone.0307235
  
  
• Yan, L., Bui, D., Li, Y., Rajeevan, N., Rowneki, M., Berry, K., Argraves, S., Huang, Y., Hynes, D.M., Cunningham, F. and Huang, G.D., 2024. Identifying veterans who benefit from nirmatrelvir-ritonavir: a target trial emulation. Clinical Infectious Diseases, 79(3), pp.643-651.doi:10.1093/cid/ciae202
  
  
• Ioannou, G.N., Berry, K., Rajeevan, N., Li, Y., Mutalik, P., Yan, L., Bui, D., Cunningham, F., Hynes, D.M., Rowneki, M. and Bohnert, A., 2023.Effectiveness of nirmatrelvir–ritonavir against the development of post–COVID-19 conditions among US veterans: a target trial emulation. Annals of internal medicine, 176(11), pp.1486-1497. doi:10.7326/M23-1394
  
  
• Bajema, K.L., Berry, K., Streja, E., Rajeevan, N., Li, Y., Mutalik, P., Yan, L., Cunningham, F., Hynes, D.M., Rowneki, M. and Bohnert, A., 2023. Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US veterans: target trial emulation studies with one-month and six-month outcomes. Annals of internal medicine, 176(6), pp.807-816. doi:10.7326/M22-3565

return to top